Macrogen Inc (038290) - Total Liabilities

Latest as of September 2025: ₩173.25 Billion KRW ≈ $117.41 Million USD

Based on the latest financial reports, Macrogen Inc (038290) has total liabilities worth ₩173.25 Billion KRW (≈ $117.41 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 038290 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.

Macrogen Inc - Total Liabilities Trend (2011–2024)

This chart illustrates how Macrogen Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Macrogen Inc asset portfolio.

Macrogen Inc Competitors by Total Liabilities

The table below lists competitors of Macrogen Inc ranked by their total liabilities.

Company Country Total Liabilities
CSP Inc
NASDAQ:CSPI
USA $25.30 Million
VLS Finance Limited
NSE:VLSFINANCE
India Rs918.78 Million
Quantum Graphite Ltd
AU:QGL
Australia AU$10.23 Million
Kron Telekomunikasyon Hizmetleri AS
IS:KRONT
Turkey TL402.17 Million
Houston American Energy Corporation
NYSE MKT:HUSA
USA $12.34 Million
Kalleback Property Invest AB
ST:KAPIAB
Sweden Skr668.05 Million
Knafaim
TA:KNFM
Israel ILA187.22 Million

Liability Composition Analysis (2011–2024)

This chart breaks down Macrogen Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 038290 equity to assets ratio to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.86 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.13 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.51 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Macrogen Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Macrogen Inc (2011–2024)

The table below shows the annual total liabilities of Macrogen Inc from 2011 to 2024.

Year Total Liabilities Change
2024-12-31 ₩152.23 Billion
≈ $103.17 Million
+54.35%
2023-12-31 ₩98.63 Billion
≈ $66.84 Million
-2.16%
2022-12-31 ₩100.80 Billion
≈ $68.31 Million
+0.27%
2021-12-31 ₩100.53 Billion
≈ $68.13 Million
+12.15%
2020-12-31 ₩89.64 Billion
≈ $60.75 Million
-20.11%
2019-12-31 ₩112.20 Billion
≈ $76.04 Million
+82.48%
2018-12-31 ₩61.49 Billion
≈ $41.67 Million
-27.17%
2017-12-31 ₩84.43 Billion
≈ $57.22 Million
+9.69%
2016-12-31 ₩76.97 Billion
≈ $52.16 Million
+32.26%
2015-12-31 ₩58.20 Billion
≈ $39.44 Million
+18.66%
2014-12-31 ₩49.05 Billion
≈ $33.24 Million
+77.29%
2013-12-31 ₩27.66 Billion
≈ $18.75 Million
-9.02%
2012-12-31 ₩30.41 Billion
≈ $20.61 Million
+107.57%
2011-12-31 ₩14.65 Billion
≈ $9.93 Million
--

About Macrogen Inc

KQ:038290 Korea Biotechnology & Medical Research
Market Cap
$79.80 Million
₩117.75 Billion KRW
Market Cap Rank
#20165 Global
#1075 in Korea
Share Price
₩11750.00
Change (1 day)
-0.42%
52-Week Range
₩10700.00 - ₩19520.00
All Time High
₩49726.89
About

Macrogen, Inc. provides genetic and genomic analysis research services in South Korea and internationally. It offers next generation sequencing (NGS) services, such as whole genome, exome, targeted, transcriptome, metagenome, epigenome, and single cell multi-omics sequencing, as well as whole genome resequencing; and standard, difficult template, and 16S/18S/26S rRNA and ITS region sequencing ser… Read more